Xencor Appoints A. Bruce Montgomery, M.D. To Board Of Directors

MONROVIA, Calif., March 19, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of A. Bruce Montgomery, M.D., to its Board of Directors.

"Bruce is a clinical development expert with an impressive record of advancing promising drug programs through the clinic, including multiple drug approvals," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "His strong medical reputation coupled with his expertise in drug development is of particular interest and a great addition to the board as we advance our growing pipeline of XmAb therapeutic antibodies, and progress clinical development of XmAb5871 and XmAb7195."

Dr. Montgomery has more than 25 years of drug development, operations and financing experience in the life science industry. He led development of the only three currently marketed antimicrobials for inhalation and initiated multiple other programs that have resulted in drug approvals. Currently, Dr. Montgomery serves as chief executive officer of Cardeas Pharma. Prior to that, he served four years as senior vice president of Gilead Sciences, and six years as chief executive officer of Corus Pharma, that he founded, and which was acquired by Gilead in 2006. Dr. Montgomery also served as executive vice president of research and development at PathoGenesis Corporation until its acquisition by Chiron in 2000. Dr. Montgomery received his bachelor's in chemistry and doctorate from the University of Washington, Seattle. Dr. Montgomery is a board certified internist and pulmonologist.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer. Currently, eight candidates that have been engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internally-discovered programs include: XmAb5871, which completed a Phase 1b/2a clinical trial for the treatment of rheumatoid arthritis and is in preparation for a clinical trial in IgG4-related disease in 2015; XmAb7195 in Phase 1a development for the treatment of asthma; and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Merck, Janssen R&D LLC, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit www.xencor.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the U.S. securities laws, including quotations from the Company's president and chief executive officer and other statements associated with Xencor's research, collaborations and its expectations regarding future therapeutic and commercial potential of Xencor's technologies, programs, drug candidates, including XmAb5871, XmAb7195, XmAb14045 and its bispecific antibody development pipeline, and intellectual property related to Xencor's XmAb technology. Because such statements are subject to risks and uncertainties, including risks associated with the process of discovering, developing and commercializing drugs that are safe and effective, actual results and the timing of events may differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Xencor's programs and technology are described in additional detail in Xencor's SEC filings. These forward-looking statements speak as of the date on which they were made, are based upon Xencor's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned not to place undue reliance on such statements and Xencor disclaims any intention or obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
Xencor
John Kuch, Vice President Finance
626-737-8013

Or

Corporate Communications Contact:
Canale Communications
Jason Spark
619-849-6005

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/xencor-appoints-a-bruce-montgomery-md-to-board-of-directors-300052732.html

SOURCE Xencor, Inc.

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.